Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313834 | 0.85 | BRD4 (0.41) | BRD4FNTAFNTBPGGT1BPI4KB | |
| SCHEMBL10275867 | 0.84 | PI4KB (0.41) | BRD4FNTAFNTBPGGT1BPI4KB | |
| SCHEMBL10275293 | 0.82 | KDM1A (0.39) | FNTAFNTBPGGT1BPI4KBMAPK14 | |
| SCHEMBL10313875 | 0.81 | BRD4 (0.39) | BRD4FNTAFNTBPGGT1BPI4KB | |
| SCHEMBL10275953 | 0.78 | PI4KB (0.45) | BRD4FNTAFNTBPGGT1BPI4KB | |
| SCHEMBL10275864 | 0.78 | FNTA (0.39) | FNTAFNTBPGGT1BMAPK14 | |
| SCHEMBL10276148 | 0.76 | BRD4 (0.41) | BRD4PI4KBKCNH2EGLN2 | |
| SCHEMBL10275567 | 0.76 | CHEK1 (0.37) | FNTAFNTBPGGT1B | |
| SCHEMBL10275286 | 0.76 | BRD4 (0.40) | BRD4FNTAFNTBPGGT1BPI4KB | |
| SCHEMBL10276423 | 0.76 | BRD4 (0.39) | BRD4FNTAFNTBPGGT1BPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | BRD4 3228/4885FNTA 3998/4885FNTB 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.